In brief
- Fisher Clinical Services has applied for DEA authorization to import DMT, 5-MeO-DMT, MDMA, and psilocybin, among other substances, strictly for clinical trials.
- Submitted on August 13, the application appeared in the Federal Register on September 24, 2026; public comments, objections, or requests for a hearing are open through October 26.
- The permit does not alter the legal status of these substances, nor is it linked to any single study: it is a routine logistical step expanding who can bring them into the country for research.
The U.S. Drug Enforcement Administration (DEA) has published an application to register a new firm as an importer of Schedule I controlled substances, including DMT, 5-MeO-DMT, MDMA, and psilocybin. The applicant is Fisher Clinical Services, a pharmaceutical logistics unit of Thermo Fisher Scientific that specializes in delivering investigational drugs to clinical trial sites.
A logistical formality, not a scientific breakthrough
Before a clinical trial involving a Schedule I substance can launch in the United States, someone must physically transport the compound into the country, which requires an importer registration from the DEA. Other distributors supplying psilocybin, MDMA, or ketamine for sponsor-backed research already operate under this exact mechanism. Fisher’s petition does not signal any new scientific discovery or regulatory clearance: it merely ensures the company can transfer materials between laboratories and hospitals running authorized trials. Such regulatory filings are becoming routine as more psychedelics advance through clinical development, a landscape covered in depth on our psychedelic science and therapy hub.
What the filing requests and its limits
According to the notice published on September 24 in the Federal Register (Docket DEA-1772), Fisher applied on August 13 for authorization to import marihuana extract, THC, MDMA, 5-MeO-DMT, DMT, and psilocybin—all Schedule I substances—alongside four Schedule II drugs, including methylphenidate. The DEA notice explicitly states that “the company plans to import the listed controlled substances solely for clinical trials” and that no other commercial activities are authorized under this registration; nor does it allow importing dosage forms approved for commercial marketing. Registered manufacturers and other interested parties have until October 26, 2026, to file written comments, raise objections, or request a hearing.
What this means
The true significance of this filing lies not in what it says about DMT or 5-MeO-DMT—there is no safety or efficacy data involved—but in what it reveals about the supply-chain infrastructure supporting research: having more licensed logistics providers helps prevent shipping bottlenecks for ongoing clinical trials evaluating DMT and 5-MeO-DMT across various phases. This administrative filing remains open to public review rather than being an immediate green light; moreover, smoother distribution between research laboratories should not be mistaken for any change in the legal status of these compounds for non-research uses.
Source
- Drug Enforcement Administration. Importer of Controlled Substances Application: Fisher Clinical Services, Inc. (I). Federal Register, September 24, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
